SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Article References

SALINAS-ESCUDERO, Guillermo et al. Economic evaluation of the use of exogenous pulmonary surfactants in preterm newborns in a Mexican population. Salud pública Méx [online]. 2012, vol.54, suppl.1, pp. s73-s81. ISSN 0036-3634.  http://dx.doi.org/10.1590/S0036-36342012000700010.

    1. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet 2008; 371(9606):75-84. [ Links ]

    2. Yost CC, Soll RF. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Library Syst Rev 2000;(2):CD001456. [ Links ]

    3. Soll RF. Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2000;(2):CD000511. [ Links ]

    4. López-Tajamana NL, Rodríguez-Zepeda JJ, Zavala-Mendoza A, Mendoza-Dominguez S, Torres-Pacheco C. Administración de surfactante exógeno en el tratamiento del síndrome de dificultad respiratoria neonatal, en su modalidad de rescate. Rev Mex Pediatr 1999;66:5-8. [ Links ]

    5. Pérez-Molina JJ, Blancas-Jacobo O, Ramírez-Valdivia JM. Enfermedad de membrana hialina: mortalidad y factores de riesgo maternos y neonatales. Ginecol Obstet Mex 2006;74:354-359. [ Links ]

    6. Fraser J, Walls M, McGuire W. Respiratory complications of preterm birth. BMJ 2004;329(7472):962-965. [ Links ]

    7. Tubman TR, Halliday HL, Normand C. Cost of surfactant replacement treatment for severe neonatal respiratory distress syndrome: a randomised controlled trial. BMJ 1990;301(6756):842-845. [ Links ]

    8. Victorian Infant Collaborative Study Group. Economic outcome for intensive care of infants of birthweight 500-999 g born in Victoria in the post surfactant era. J Pediatr Child Health 1997;33:202-208. [ Links ]

    9. Phibbs CS, Phibbs RH, Wakeley A, Schlueter MA, Sniderman S, Tooley WH. Cost effects of surfactant therapy for neonatal respiratory distress syndrome. J Pediatr 1993;123:953-962. [ Links ]

    10. Pejaver RK, al Hifzi I, Aldussari S. Surfactant replacement therapy—economic impact. Indian J Pediatr 2001;68:501-505. [ Links ]

    11. al Umran K, Yaseen H. Cost-effectiveness of surfactant replacement therapy in a developing country. J Trop Pediatr 1997;43:167-169. [ Links ]

    12. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146:473-481. [ Links ]

    13. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004;329(7459):224-227. doi: 10.1136. [ Links ]

    14. Villasis KMA, Rendón MME, García JH, Escamilla NA, Salinas EG, Martínez VS, et al. Revisión sistemática y meta-análisis sobre la efectividad del surfactante bovino como tratamiento de prematuros con síndrome de dificultad respiratoria. Bol Med Hosp Infant Mex 2010;67:477-491. [ Links ]

    15. Seger N, Soll R. Animal derived surfactant extract for treatment of respiratory distress syndrome. Cochrane Database Syst Rev 2009;2:CD007836. [ Links ]

    16. Secretaría de Salud. Consejo de Salubridad General. Guía para la conducción de estudios de evaluación económica para la actualización del Cuadro Básico de Insumos del Sector Salud en México. México: SSA, 2008. [ Links ]

    17. Lorch SA, Cnaan A, Barnhart K. Cost-effectiveness of inhaled nitric oxide for the management of persistent pulmonary hypertension of the newborn. Pediatrics 2004;114:417-426. [ Links ]

    18. Two-year follow-up of infants treated for neonatal respiratory distress syndrome with bovine surfactant. Survanta Multidose Study Group. J Pediatr 1994;124:962-967. [ Links ]

    19. Consejo Nacional de Población. Proyecciones de la Población en México 2005-2050.México. [Accessed 2009 May]. Available at: http://www.conapo.gob.mx/index.php?option=com_content&view=article&id=36&Itemid=234 [ Links ]

    20. Secretaría de Salud. Dirección General de Información en Salud. Base de datos de nacidos vivos registrados 1990-2007. Sistema Nacional de Información en Salud (SINAIS). México. [Accessed 2009 April]. Available at: http://www.sinais.salud.gob.mx. [ Links ]

    21. World Health Organization. The World Health Report 2000. Health Systems: Improving Performance. Geneva Switzerland. [Accessed 2009 October]. Available at: http://www.who.int/whr/2000/en/whr00_en.pdf [ Links ]

    22. Instituto Nacional de Estadística y Geografía. Sistema de Cuentas Nacionales. Tercer Trimestre 2009. [Accessed 2009 November]. Available at: http://dgcnesyp.inegi.org.mx/cgi-win/bdiecoy.exe/572?s=est&c=12546 [ Links ]

    23. Consejo Nacional de Población. Indicadores demográficos básicos 1990-2030. [Accessed 2009 June]. Available at: http://www.conapo.gob.mx/index.php?option=com_content&view=article&id=125&Itemid=193 [ Links ]

    24. Banco de México. Mercado cambiario. [Accessed 2009 November]. Available at: http://www.banxico.org.mx/portal-mercado-cambiario/index.html [ Links ]

    25. Profit J, Lee D, Zupancic JA, Papile L, Gutierrez C, Goldie SJ, et al. Clinical benefits, costs, and cost-effectiveness of neonatal intensive care in Mexico. PLoS Med 2010;7:e1000379. doi:10.1371/journal.pmed.1000379. [ Links ]

    26. Mugford M, Howard S. Cost effectiveness of surfactant replacement in preterm babies. Pharmacoeconomics 1993;3:362-373. [ Links ]

    27. Ainsworth SB, Milligan DW. Surfactant therapy for respiratory distress syndrome in premature neonates: a comparative review. Am J Respiratory Med 2002;1:417-433. [ Links ]

    28. Mugford M. Cost effectiveness of prevention and treatment of neonatal respiratory distress (RDS) with exogenous surfactant: what has changed in the last three decades? Early Hum Dev 2006;82:105-115. [ Links ]